Escape Mechanisms in Schistosomiasis

  • M. Capron
  • O. Duvaux-Miret
  • A. Capron
Conference paper


Survival and growth of infectious organisms in the face of the immune response mounted by their immunocompetent hosts is made possible through one of two strategies: one is to outrun rejection by fast replication and/or mutation, as observed in some bacterial or viral infections; the other is to impair development or expression of immunity so as to evade the deleterious consequences of the host’s counter-attack. Indeed, it is now recognized that in most infections, it is the infectious organism, that determines whether or not to allow itself to be rejected by immune effectors. This is clearly the case of parasites which in general induce chronic infections and are thus confronted for months and often years with the immune response that they have to maintain within limits compatible with both their own survival and that of their mammalian hosts. This leads in many instances to the refined elaboration in these organisms of a complex network of processes allowing them to escape the defence mechanisms of their host. Such a complexity gives the expression of immunity in parasitic diseases a dynamic aspect reflecting the permanent balance between effector and regulatory mechanisms (Capron and Dessaint, in press).


Adult Worm Molecular Mimicry Antibody Isotype Infected Snail Infectious Organism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amiri P, Locksley RM, Parslow TG, Sadick M, Rector E, Ritter D, Mc Kerrow JH, (1992) Nature 356:604–607PubMedCrossRefGoogle Scholar
  2. Auriault C, Joseph M, Tartar A, Bout D, Tonnel AB, Capron A (1985) Int J Immunopharmacol 7:73–79PubMedCrossRefGoogle Scholar
  3. Butterworth AE, Bensted-Smith R, Capron A, Duiton PR, Dunne DW, Grzych JM, Kariaki HC, Khalife J, Koech D, Muyambi M, Ouma JH, arap Siongok JK, Sturrock RF (1987) Parasitology 94:281–300PubMedCrossRefGoogle Scholar
  4. Butterworth AE, Vadas MA, Martz E, Sher A (1979) J Immunol 122:1314–1321PubMedGoogle Scholar
  5. Capron A, Capron M, Joseph M, Dissous C, Auriault C (1984) New approaches to vaccine development, In: Bell R, Torrigiani G (eds) Schwabbe and Co Ag, Basel, p 460Google Scholar
  6. Capron A, Dessaint JP (1985) Ann Rev Immunol 3:455–476CrossRefGoogle Scholar
  7. Capron A, Dessaint JP (in press) Adv NeuroimmunolGoogle Scholar
  8. Capron M, Tomassini M, Van der Vorst E, Kusnierz JP, Papin JP, Capron A (1988) Cr Acad Sc Immunol 307:397–402Google Scholar
  9. Dunne D, Butterworth AE, Fulford AJC, Kariuki HC, Langley JG, Ouma JH, Capron A, Pierce RJ, Sturrock RF (1992) Eur J Immunol 22:1483–1494PubMedCrossRefGoogle Scholar
  10. Duvaux-Miret O, Capron A (1991) Adv Neuroimmunol 1:41–57CrossRefGoogle Scholar
  11. Duvaux-Miret O, Dissous C, Gautron JP, Pattou E, Kordon C, Capron A (1990) New Biol 2:93–99PubMedGoogle Scholar
  12. Duvaux-Miret O, Stefano GB, Smith EM, Dissous C, Capron A (1992) Proc Natl Acad Sci USA 89:778–781PubMedCrossRefGoogle Scholar
  13. Grzych JM, Capron M, Bazin H, Capron A (1982) J Immunol 129:2739–2743PubMedGoogle Scholar
  14. Grzych JM, Capron M, Dissous C, Capron A (1984) J Immunol 133:998–1004PubMedGoogle Scholar
  15. Grzych JM, Grezel D, Xu CB, Neyrinck JL, Capron M, Ouma JH, Butterworth AE, Capron A (in press) J ImmunolGoogle Scholar
  16. Grzych JM, Pearce EJ, Cheever A, Caulada ZA, Caspar P, Heiny S, Lewis F, Sher A (1991) J Immunol 146:1322–1327PubMedGoogle Scholar
  17. Hagan P, Blumenthal UJ, Dunne D, Simpson AJG, Wilkins HA (1991) Nature 349–243Google Scholar
  18. Johnson HM, Smith EM, Torres BA, Blalock JE (1982) Proc Natl Acad Sci USA 79:4171–4174PubMedCrossRefGoogle Scholar
  19. Johnson HW, Torres BA, Smith EM, Dion LD, Blalock JE (1984) J Immunol 132: 246–250PubMedGoogle Scholar
  20. Khalife J, Capron M, Capron A Grzych JM, Butterworth AE, Dunne DW, Ouma JH (1986) J Exp Med 164:1626–1640PubMedCrossRefGoogle Scholar
  21. Khalife J, Dunne DW, Richardson BA, Mazza G, Thorne KJ, Capron A, Butterworth AE (1989) J Immunol 142:4422–4427PubMedGoogle Scholar
  22. Mazingue C, Stadler B, Quatannens B, Capron A, De Weck A (1986) Int Archs Allergy Appl Immunol 80:347–354CrossRefGoogle Scholar
  23. Pearce E, Appleton J (in press) Parasitol TodayGoogle Scholar
  24. Pearce EJ, Caspar P, Grzych JM, Lewis FA, Sher A (1991) J Exp Med 173:159–166PubMedCrossRefGoogle Scholar
  25. Pearce EJ, Sher A (1991) Exp Parasitol 73:110–116PubMedCrossRefGoogle Scholar
  26. Rihet P, Demeure CE, Bourgeois A, Prata A, Dessein AJ (1991) Eur J Immunol 21:2679–2686PubMedCrossRefGoogle Scholar
  27. Sher A, Hall BF, Vadas MA (1978) J Exp Med 148:46–52PubMedCrossRefGoogle Scholar
  28. Shipp MA, Stefano GB, D’Adamio L, Switzer SN, Howard FD, Sinisterra J, Scharrer B, Reinherz E (1990) Nature 347:394–396PubMedCrossRefGoogle Scholar
  29. Smith EM, Hughes TK, Leung MK, Stefano GB (1991) Adv. Neuroimmunol. 1:7–16CrossRefGoogle Scholar
  30. Stefano GB, Leung MK, Zhao X, Scharrer B (1989) Proc Natl Acad Sci USA 86:626–630PubMedCrossRefGoogle Scholar
  31. Stefano GB, Smith DE, Smith D, Hughes TK (in press) MSH can deactivate both TNF stimulated and spontaneously active immunocytes In: Boer H, Maat A (eds) Molluscan Neurobiology, Elsevier North Holland, AmsterdamGoogle Scholar
  32. Torpier G, Capron A, Ouaïssi MA (1979) Nature 278:447–449PubMedCrossRefGoogle Scholar
  33. Van Epps DE, Mason MM (1990) Modulation of leukocyte migration by alphamelanocyte stimulating hormone In: Florey E, Stefano G (eds) Comparative Neuropeptide Pharmacology, Manchester University Press, UK p 335Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • M. Capron
    • 1
  • O. Duvaux-Miret
    • 1
  • A. Capron
    • 1
  1. 1.Centre d’Immunologie et de Biologie Parasitaire, Unité Mixte INSERM U167 - CNRS 624Institut PasteurLille CédexFrance

Personalised recommendations